Join the movement to help increase access to cervical cancer screening

FDA-approved self-collection for cervical cancer screening opens the door to a less invasive, more comfortable screening option, helping to improve accessibility and equity in healthcare.

Diagnostic barriers exist: 60% of cervical cancer cases occur in unscreened or underscreened patients.[1]

Common cervical cancer screening barriers for many patients, including:[2]

- **Lack of awareness about importance of screening**
- **Fear or anxiety with cervical exams and clinician-collection**
- **Social, religious or socioeconomic factors**
- **Physical and geographic inaccessibility**

1 in 10

Black and Hispanic women never had a Pap test or OB/GYN visit.[3]

Screening plays a crucial role in early detection and prevention of cervical cancer

The FDA has approved self-collection for cervical cancer screening in healthcare settings.* Now patients can collect their own sample without the need for a traditional endocervical specimen collection (Pap Test) or pelvic exam. This can potentially increase screening participation rates, and more people being screened results in fewer cases of cervical cancer.[4,5]

*Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.

Cervical cancer is preventable with appropriate vaccination, screening, and management.[6]

BD

Shape the future of cervical cancer screening with BD

The BD Onclarity™ HPV Assay with extended genotyping is the first and only HPV test supported by all ASCCP extended genotyping guidelines and offers self-collection in a healthcare setting, empowering equitable access to screening.[7]



Ask your laboratory for the BD Copan FLOQSwab® for HPV Self Collection (SKU:445436)

Leverage a seamless clinical workflow with dry transport

The BD Onclarity™ HPV Assay workflow has been clinically validated and offers a convenient logistical chain with dry transport to laboratories within 30 days of collection.

Clinically validated workflow, comparable sensitivity
Self-collected vaginal samples have comparable sensitivity of CIN2+ detection[8]

Fewer invalid results, more actionable insights
Self-collected samples with lowest proportion of invalid results compared to other PCR-based HPV tests[9,10]

Lab efficiency through automation and integration
Available out of BD SurePath™ and Hologic ThinPrep® Pap Tests, and self-collected vaginal samples on BD COR™ System

Cervical cancer can be eliminated as a public health issue by overcoming disparities in access.

Find a lab that can provide **BD Onclarity™ HPV Assay** and **HPV Self-Collection swabs** for your patients.

References:
1. Benard VB et al. *Cancer Med*. 2021; 10 (12): 4127-4137.
2. Zeno EE et al. PLoS One. 2022;17(10):e0274974. doi: 10.1371/journal.pone.0274974
3. Aust N Z et al. *J Obstet Gynaecol*. 2021;61(1):135-141. doi: 10.1111/ajo.13285.
4. Lozar T et al. *Int J Womens Health*. 2021;13:841–59.
5. Arbyn M et al. *Int J Cancer*. 2021;148(2):277–84.
6. World Health Organization. Cervical Cancer Elimination Initiative. Available at: https://www.who.int/initiatives/cervical-cancerelimination-initiative. Accessed 20 May 2024.
7. ASCCP. Public Comments on Draft Recommendations for Extended Genotyping. Accessed December 2024.
8. Arbyn M et al. *BMJ*. 2018;363:k4823.
9. Cobas® HPV Test Package Insert. US 2024.
10. Martinelli M, Ardashel Latsuzbaia, Bonde J, et al. Performance of BD Onclarity HPV assay on FLOQSwabs vaginal self-samples. *Microbiology spectrum*. Published online February 7, 2024.

bd.com